ine powder to provide topical, local analgesia to
reduce the pain associated with peripheral IV insertions or blood draws.
Zingo's rapid onset of action allows intravenous line placement or
venipuncture to begin one to three minutes after administration. In
clinical trials, the most common adverse events with Zingo were redness,
red dots and swelling. For full Zingo prescribing information, go to
About Anesiva and its Diverse Pipeline of Pain Products
Anesiva, Inc. is a late-stage biopharmaceutical company that seeks to
be the leader in the development and commercialization of novel therapeutic
treatments for pain. The company has one FDA-approved product, Zingo(TM),
for the reduction of pain associated with peripheral venous access
procedures in children ages three to 18. The second product in Anesiva's
pipeline, Adlea(TM), has been shown to reduce pain after only a single
administration for weeks to months in multiple settings in numerous
mid-stage clinical trials for site-specific, acute and chronic,
moderate-to-severe pain. Anesiva is based in South San Francisco, CA. For
more information about Anesiva's leadership in the development of products
for pain management, and an overview of the clinical challenges being
addressed by its product candidates, go to http://www.anesiva.com.
This press release includes "forward-looking statements" within the
meaning of the safe harbor provisions of the United States Private
Securities Litigation Reform Act of 1995. Words such as "expect,"
"estimate," "project," "budget," "forecast," "anticipate," "intend,"
"plan," "may," "will," "could," "should," "believes," "predicts,"
"potential," "continue," and similar expressions are intended to identify
such forward-looking statements. Forward- looking statements inPage: 1 2 3 4 Related biology technology :1
. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals2
. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)3
. FDA Accepts Ranexa(R) sNDA and NDA for Filing4
. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes5
. Imaging Diagnostic Systems Accepts Resignations of Outside Directors6
. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile7
. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children8
. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program9
. Anesiva Signs Co-Promotion and Distribution Agreement With Sagent Pharmaceuticals for Zingo(TM) in U.S. Hospitals10
. Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)11
. Anesiva Announces Submission of Supplemental New Drug Application for Zingo(TM) to Reduce Pain Associated With Needle Insertion Procedures in Adults